Authorized purpose: SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Clinical role
MRI acquisition, reconstruction, display, and release-specific workflow support.
Images and patients
MRI · Head/Extremities
Key limitation
Keep in mind: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release. SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Head/Extremities Input: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
Who uses it?Intended users: Qualified MRI technologists and physicians trained in magnetic resonance imaging.
What does the software produce?Output: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
What is its most important limitation?Key limitation: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release. SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Clinical takeaway. Clinical role: SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports nonclinical performance testing of the AIR Recon DL feature for SNR, sharpness and low contrast detectability, which passed defined acceptance criteria, plus simulations and analyses for installed base magnet types. Clinically, objective measures of in vivo images were analyzed, and a reader study in which radiologists rated images with and without AIR Recon DL showed better SNR and equivalent or better sharpness; radiologists uniformly preferred AIR Recon DL images. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release. SIGNA 7.0T is a whole-body MR scanner for diagnostic and spectroscopic images, maps, spectra, and dynamic images of structures and functions of the head and extremities in patients over the labeled weight limit.
The exact FDA document reports nonclinical performance testing of the AIR Recon DL feature for SNR, sharpness and low contrast detectability, which passed defined acceptance criteria, plus simulations and analyses for installed base magnet types. Clinically, objective measures of in vivo images were analyzed, and a reader study in which radiologists rated images with and without AIR Recon DL showed better SNR and equivalent or better sharpness; radiologists uniformly preferred AIR Recon DL images. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "These tests were designed to evaluate the AIR Recon DL feature and its impact on image quality, including SNR, sharpness, and low contrast detectability." … "The nonclinical testing passed the defined acceptance criteria, and did not identify any adverse impacts to image quality or other concerns related to safety and performance.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports nonclinical performance testing of the AIR Recon DL feature for SNR, sharpness and low contrast detectability, which passed defined acceptance criteria, plus simulations and analyses for installed base magnet types. Clinically, objective measures of in vivo images were analyzed, and a reader study in which radiologists rated images with and without AIR Recon DL showed better SNR and equivalent or better sharpness; radiologists uniformly preferred AIR Recon DL images. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "These tests were designed to evaluate the AIR Recon DL feature and its impact on image quality, including SNR, sharpness, and low contrast detectability." … "The nonclinical testing passed the defined acceptance criteria, and did not identify any adverse impacts to image quality or other concerns related to safety and performance.". Read from the exact FDA decision document on 2026-11-14.
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K211118
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K211118.
PopulationThe labeled population and test materials for exact submission K211118; a general clinical study population is not established here.
Scopeexact submission
Tested versionSIGNA 7.0T (K211118)
IndependenceSponsor or vendor study
K211118
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-2483-2024 is associated with native exact submission identifier K211118. Status: Open, Classified. Product: SIGNA 7.0T, with affected software versions: 7T29.1, MR30.1; Nuclear Magnetic Resonance Imaging System. Reason: GE HealthCare has become aware that for certain MR systems, the system predicted B1+RMS value can exceed the B1+RMS user prescribed limit when scanning in Low SAR Mode and the following two conditions are met: 1. 2D FSE T2 FLAIR OR T2 FLAIR Propeller imaging sequence is selected, AND 2. the Optimized T2 FLAIR sequence option is turned off OR not included in the MR configuration. If this occurs, it can result in...
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Native exact-submission identifier match from the openFDA candidate snapshot accessed 2026-09-04 with source snapshot date 2026-09-02. Source URL: https://api.fda.gov/device/recall.json?search=product_res_number.exact%3A%22Z-2483-2024%22&limit=1. This does not establish exact installed serial, lot, unit, or software-version applicability.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.
Current vendor material is product-family context for K211118 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
29Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: MAGNETOM Terra and Terra.X with syngo MR XA60A provide 7T proton MRI of the head and extremities, sodium head imaging, and phosphorus spectroscopy of the body excluding the head within labeled limits.
Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.
Authorized purpose: Vantage Fortian and Orian 1.5T produce diagnostic MR images of the head and body, including labeled noncontrast angiography, for trained technologists and physician interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.